Kevin Hogan Brings a Fresh Perspective to MarketScale’s EdTech Publication

 

MarketScale is always growing its network of contributors across industries. On this Business Casual snippet, Voice of B2B Daniel Litwin welcomes Kevin Hogan, MarketScale newest education technology contributor and writer, to shed light on his partnership with MarketScale and the EdTech content to come.

A forward thinking media executive with more than 25 years experience building brands and audiences online, in print, and face to face, Hogan is an acclaimed writer, editor, and commentator covering the intersection of society and technology, especially education technology. His experience includes Senior Editor at MIT Technology Review, Editor-In-Chief at The Manufacturer Magazine, Executive Editor at Scholastic Administrator, and most recently, over 12 years as the Managing Director of Content at Tech & Learning.

His most recent content for MarketScale include content on EdTech conferences’ shifts to online, the state of EdTech funding, and how EdTech leaders are bracing for a post-pandemic fall semester

His podcast show, Remote Possibilities, launches soon.

For the latest news, videos, and podcasts in the Education Technology Industry, be sure to subscribe to our industry publication.

 

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Latest

NRF 2022 Retail's Big Show
What’s in the Shopping Cart for the 2022 National Retail Federation’s Big Show?
January 14, 2022
 In just a few short days, from January 16th through the 18th, the National Retail Federation will launch Retail’s Big Show in the shopping capital of the world, New York City. As retail Read more
Schools Struggle to Reach Their Education Technology Goals. Here’s Why and How To Fix It.
January 14, 2022
As we hit the two-year mark of the COVID-19 pandemic, the education sector continues to struggle in adjusting to virtual and hybrid education at scale. In 2020, McKinsey estimated that, due to COVID Read more
85% of Clinical Drug Trials Face Delays. What's the True Cost?
85% of Clinical Drug Trials Face Delays. What’s the True Cost?
January 14, 2022
  Clinical trials can save lives and provide new ways to treat disease. The industry estimates that 85% of all clinical trials face delays due to patient enrollment. Understanding that challenge Read more